Adenosine receptors: pharmacology, functions and therapeutic aspects
Saved in:
| Other Authors: | |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
New York
Nova Biomedical
[2014]
|
| Series: | Pharmacology-research, safety testing, and regulation series
|
| Subjects: | |
| Physical Description: | 1 online resource |
| ISBN: | 9781634634717 1634634713 |
Staff View
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV044358913 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 170620s2014 |||| o||u| ||||||eng d | ||
| 020 | |a 9781634634717 |9 978-1-63463-471-7 | ||
| 020 | |a 1634634713 |9 1-63463-471-3 | ||
| 035 | |a (ZDB-4-NLEBK)ocn898279089 | ||
| 035 | |a (OCoLC)898279089 | ||
| 035 | |a (DE-599)BVBBV044358913 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 082 | 0 | |a 615/.7 |2 23 | |
| 245 | 1 | 0 | |a Adenosine receptors |b pharmacology, functions and therapeutic aspects |c Kasandra Warrick, editor |
| 264 | 1 | |a New York |b Nova Biomedical |c [2014] | |
| 264 | 4 | |c © 2015 | |
| 300 | |a 1 online resource | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Pharmacology-research, safety testing, and regulation series | |
| 505 | 8 | |a ADENOSINE RECEPTORS: PHARMACOLOGY, FUNCTIONS AND THERAPEUTIC ASPECTS; ADENOSINE RECEPTORS: PHARMACOLOGY, FUNCTIONS AND THERAPEUTIC ASPECTS; Library of Congress Cataloging-in-Publication Data; Contents; Preface; Chapter I: Anti-Inflammatory and Immunosuppressive Actions of Adenosine A2A Receptor in Ischemia-Reperfusion Injury after Organ Transplantation; Abstract; Introduction; 1.1. Adenosine and Adenosine Receptors; 1.2. Anti-Inflammatory Mechanisms of A2AR Activation; 1.3. Role of A2AR in Lung IRI; 1.4. Role of A2AR in Kidney IRI; 1.5. Role of A2AR in Cardiac IRI | |
| 505 | 8 | |a 1.6. Role of A2AR in Liver IRI1.7. Role of A2AR in Pancreas IRI; 1.8. Clinical Experience with A2AR Agonists; Conclusion; References; Chapter II: Adenosine Receptors in the Vasculature: Physiology, Pharmacology and Therapeutic Perspectives; Abstract; 1. Introduction; 2. Adenosine Bioavailability; 2.1. Adenosine Formation and Catabolism; 2.2. Adenosine Transport; 2.2.1. Equilibrative Nucleoside Transporters; 2.2.2. Concentrative Transporters; 2.2.3. Adenosine Transport Inhibition; 3. Adenosine Receptors; 3.1. Interplay between Nucleoside Transport and Adenosine Receptor Activity | |
| 505 | 8 | |a 3.2. Molecular Structure and Ligand Binding of Adenosine Receptors3.3. Signaling Pathways; 3.4. Adenosine Receptors Distribution; 3.4.1. Vascular Wall: Intima, Media and Adventitia; 3.4.2. Adenosine Receptors in the Vascular Wall; 3.4.2.1. Intima Layer; 3.4.2.2. Media Layer; 3.4.2.3. Adventitial Layer; 4. Therapeutic Potential of Adenosine Receptor Ligands; Conclusion; References; Chapter III: Insights on the Role of Adenosine and Adenosine Receptors on Melanoma: New Therapeutic Strategies; Abstract; Introduction; 1. Adenosine; 1.1. Formation and Metabolism; 1.2. Adenosine Receptors | |
| 505 | 8 | |a 1.3. Adenosine Receptors in Cancer1.3.1. Adenosine Receptors in Melanoma; 2. Melanoma; 2.1. Signalling Pathways Involved in Melanoma Progression; 2.1.1. Mitogen-Activated Protein Kinase Pathway; 2.1.2. Phosphatidylinositol-3-Kinase Pathway; 2.2. Therapies for Metastatic Melanoma; 3. New Insights; 3.1. Characterization of Adenosine Receptor Expression in Melanoma Cell Lines; 3.2. Inosine Strongly Enhances Human C32 Melanoma Cells Proliferation through PLC-PKC-MEK1/2-ERK1/2 and PI3K Pathways | |
| 505 | 8 | |a 3.3. Potentiation of Cytotoxicity of Paclitaxel in Combination with Cl-IB-MECA in Human C32 Metastatic Melanoma Cells: A New Possible Therapeutic Strategy for Melanoma3.4. Combination of Cl-IB-MECA with Paclitaxel Is a Highly Effective Cytotoxic Therapy Causing mTOR-Dependent Autophagy and Mitotic Catastrophe on Human Melanoma Cells; 3.5. The Combination of Cl-IB-MECA with Paclitaxel: A New Anti-Metastatic Therapeutic Strategy for Melanoma; Conclusion; References; Chapter IV: Urinary Bladder Disorders: Is Adenosine Friend or Foe?; Abstract; Introduction | |
| 505 | 8 | |a Adenosine is a ubiquitous adenine base purine that mediates diverse biological and physiological processes in the cardiovascular system, both in cardiac and vascular tissues. Adenosine was reported to be involved in smooth muscle contraction, neurotransmission/neuromodulation, immune response and inflammation, platelet aggregation and modulation of cardiac function. Adenosine availability, in the extracellular space, depends on its release from a variety of cell types, as a result of adenosine triphosphate (ATP) enzymatic breakdown of both intra- and extracellular adenine nucleotides and intra | |
| 650 | 7 | |a MEDICAL / Pharmacology |2 bisacsh | |
| 650 | 7 | |a Adenosine / Physiological effect |2 fast | |
| 650 | 7 | |a Adenosine / Receptors |2 fast | |
| 650 | 4 | |a Medizin | |
| 650 | 4 | |a Adenosine |x Receptors |a Adenosine |x Physiological effect | |
| 700 | 1 | |a Warrick, Kasandra |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |a Warrick, Kasandra |t Adenosine Receptors : Pharmacology, Functions and Therapeutic Aspects |d Hauppauge : Nova Science Publishers, Inc.,c2014 |z 9781634634540 |
| 912 | |a ZDB-4-NLEBK | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-029761544 | ||
Record in the Search Index
| _version_ | 1804177605079859200 |
|---|---|
| any_adam_object | |
| author2 | Warrick, Kasandra |
| author2_role | edt |
| author2_variant | k w kw |
| author_facet | Warrick, Kasandra |
| building | Verbundindex |
| bvnumber | BV044358913 |
| collection | ZDB-4-NLEBK |
| contents | ADENOSINE RECEPTORS: PHARMACOLOGY, FUNCTIONS AND THERAPEUTIC ASPECTS; ADENOSINE RECEPTORS: PHARMACOLOGY, FUNCTIONS AND THERAPEUTIC ASPECTS; Library of Congress Cataloging-in-Publication Data; Contents; Preface; Chapter I: Anti-Inflammatory and Immunosuppressive Actions of Adenosine A2A Receptor in Ischemia-Reperfusion Injury after Organ Transplantation; Abstract; Introduction; 1.1. Adenosine and Adenosine Receptors; 1.2. Anti-Inflammatory Mechanisms of A2AR Activation; 1.3. Role of A2AR in Lung IRI; 1.4. Role of A2AR in Kidney IRI; 1.5. Role of A2AR in Cardiac IRI 1.6. Role of A2AR in Liver IRI1.7. Role of A2AR in Pancreas IRI; 1.8. Clinical Experience with A2AR Agonists; Conclusion; References; Chapter II: Adenosine Receptors in the Vasculature: Physiology, Pharmacology and Therapeutic Perspectives; Abstract; 1. Introduction; 2. Adenosine Bioavailability; 2.1. Adenosine Formation and Catabolism; 2.2. Adenosine Transport; 2.2.1. Equilibrative Nucleoside Transporters; 2.2.2. Concentrative Transporters; 2.2.3. Adenosine Transport Inhibition; 3. Adenosine Receptors; 3.1. Interplay between Nucleoside Transport and Adenosine Receptor Activity 3.2. Molecular Structure and Ligand Binding of Adenosine Receptors3.3. Signaling Pathways; 3.4. Adenosine Receptors Distribution; 3.4.1. Vascular Wall: Intima, Media and Adventitia; 3.4.2. Adenosine Receptors in the Vascular Wall; 3.4.2.1. Intima Layer; 3.4.2.2. Media Layer; 3.4.2.3. Adventitial Layer; 4. Therapeutic Potential of Adenosine Receptor Ligands; Conclusion; References; Chapter III: Insights on the Role of Adenosine and Adenosine Receptors on Melanoma: New Therapeutic Strategies; Abstract; Introduction; 1. Adenosine; 1.1. Formation and Metabolism; 1.2. Adenosine Receptors 1.3. Adenosine Receptors in Cancer1.3.1. Adenosine Receptors in Melanoma; 2. Melanoma; 2.1. Signalling Pathways Involved in Melanoma Progression; 2.1.1. Mitogen-Activated Protein Kinase Pathway; 2.1.2. Phosphatidylinositol-3-Kinase Pathway; 2.2. Therapies for Metastatic Melanoma; 3. New Insights; 3.1. Characterization of Adenosine Receptor Expression in Melanoma Cell Lines; 3.2. Inosine Strongly Enhances Human C32 Melanoma Cells Proliferation through PLC-PKC-MEK1/2-ERK1/2 and PI3K Pathways 3.3. Potentiation of Cytotoxicity of Paclitaxel in Combination with Cl-IB-MECA in Human C32 Metastatic Melanoma Cells: A New Possible Therapeutic Strategy for Melanoma3.4. Combination of Cl-IB-MECA with Paclitaxel Is a Highly Effective Cytotoxic Therapy Causing mTOR-Dependent Autophagy and Mitotic Catastrophe on Human Melanoma Cells; 3.5. The Combination of Cl-IB-MECA with Paclitaxel: A New Anti-Metastatic Therapeutic Strategy for Melanoma; Conclusion; References; Chapter IV: Urinary Bladder Disorders: Is Adenosine Friend or Foe?; Abstract; Introduction Adenosine is a ubiquitous adenine base purine that mediates diverse biological and physiological processes in the cardiovascular system, both in cardiac and vascular tissues. Adenosine was reported to be involved in smooth muscle contraction, neurotransmission/neuromodulation, immune response and inflammation, platelet aggregation and modulation of cardiac function. Adenosine availability, in the extracellular space, depends on its release from a variety of cell types, as a result of adenosine triphosphate (ATP) enzymatic breakdown of both intra- and extracellular adenine nucleotides and intra |
| ctrlnum | (ZDB-4-NLEBK)ocn898279089 (OCoLC)898279089 (DE-599)BVBBV044358913 |
| dewey-full | 615/.7 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615/.7 |
| dewey-search | 615/.7 |
| dewey-sort | 3615 17 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04913nmm a2200457zc 4500</leader><controlfield tag="001">BV044358913</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">170620s2014 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781634634717</subfield><subfield code="9">978-1-63463-471-7</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1634634713</subfield><subfield code="9">1-63463-471-3</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-4-NLEBK)ocn898279089</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)898279089</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV044358913</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615/.7</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Adenosine receptors</subfield><subfield code="b">pharmacology, functions and therapeutic aspects</subfield><subfield code="c">Kasandra Warrick, editor</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York</subfield><subfield code="b">Nova Biomedical</subfield><subfield code="c">[2014]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">© 2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Pharmacology-research, safety testing, and regulation series</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">ADENOSINE RECEPTORS: PHARMACOLOGY, FUNCTIONS AND THERAPEUTIC ASPECTS; ADENOSINE RECEPTORS: PHARMACOLOGY, FUNCTIONS AND THERAPEUTIC ASPECTS; Library of Congress Cataloging-in-Publication Data; Contents; Preface; Chapter I: Anti-Inflammatory and Immunosuppressive Actions of Adenosine A2A Receptor in Ischemia-Reperfusion Injury after Organ Transplantation; Abstract; Introduction; 1.1. Adenosine and Adenosine Receptors; 1.2. Anti-Inflammatory Mechanisms of A2AR Activation; 1.3. Role of A2AR in Lung IRI; 1.4. Role of A2AR in Kidney IRI; 1.5. Role of A2AR in Cardiac IRI</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">1.6. Role of A2AR in Liver IRI1.7. Role of A2AR in Pancreas IRI; 1.8. Clinical Experience with A2AR Agonists; Conclusion; References; Chapter II: Adenosine Receptors in the Vasculature: Physiology, Pharmacology and Therapeutic Perspectives; Abstract; 1. Introduction; 2. Adenosine Bioavailability; 2.1. Adenosine Formation and Catabolism; 2.2. Adenosine Transport; 2.2.1. Equilibrative Nucleoside Transporters; 2.2.2. Concentrative Transporters; 2.2.3. Adenosine Transport Inhibition; 3. Adenosine Receptors; 3.1. Interplay between Nucleoside Transport and Adenosine Receptor Activity</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">3.2. Molecular Structure and Ligand Binding of Adenosine Receptors3.3. Signaling Pathways; 3.4. Adenosine Receptors Distribution; 3.4.1. Vascular Wall: Intima, Media and Adventitia; 3.4.2. Adenosine Receptors in the Vascular Wall; 3.4.2.1. Intima Layer; 3.4.2.2. Media Layer; 3.4.2.3. Adventitial Layer; 4. Therapeutic Potential of Adenosine Receptor Ligands; Conclusion; References; Chapter III: Insights on the Role of Adenosine and Adenosine Receptors on Melanoma: New Therapeutic Strategies; Abstract; Introduction; 1. Adenosine; 1.1. Formation and Metabolism; 1.2. Adenosine Receptors</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">1.3. Adenosine Receptors in Cancer1.3.1. Adenosine Receptors in Melanoma; 2. Melanoma; 2.1. Signalling Pathways Involved in Melanoma Progression; 2.1.1. Mitogen-Activated Protein Kinase Pathway; 2.1.2. Phosphatidylinositol-3-Kinase Pathway; 2.2. Therapies for Metastatic Melanoma; 3. New Insights; 3.1. Characterization of Adenosine Receptor Expression in Melanoma Cell Lines; 3.2. Inosine Strongly Enhances Human C32 Melanoma Cells Proliferation through PLC-PKC-MEK1/2-ERK1/2 and PI3K Pathways</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">3.3. Potentiation of Cytotoxicity of Paclitaxel in Combination with Cl-IB-MECA in Human C32 Metastatic Melanoma Cells: A New Possible Therapeutic Strategy for Melanoma3.4. Combination of Cl-IB-MECA with Paclitaxel Is a Highly Effective Cytotoxic Therapy Causing mTOR-Dependent Autophagy and Mitotic Catastrophe on Human Melanoma Cells; 3.5. The Combination of Cl-IB-MECA with Paclitaxel: A New Anti-Metastatic Therapeutic Strategy for Melanoma; Conclusion; References; Chapter IV: Urinary Bladder Disorders: Is Adenosine Friend or Foe?; Abstract; Introduction</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Adenosine is a ubiquitous adenine base purine that mediates diverse biological and physiological processes in the cardiovascular system, both in cardiac and vascular tissues. Adenosine was reported to be involved in smooth muscle contraction, neurotransmission/neuromodulation, immune response and inflammation, platelet aggregation and modulation of cardiac function. Adenosine availability, in the extracellular space, depends on its release from a variety of cell types, as a result of adenosine triphosphate (ATP) enzymatic breakdown of both intra- and extracellular adenine nucleotides and intra</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Pharmacology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Adenosine / Physiological effect</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Adenosine / Receptors</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medizin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Adenosine</subfield><subfield code="x">Receptors</subfield><subfield code="a">Adenosine</subfield><subfield code="x">Physiological effect</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Warrick, Kasandra</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="a">Warrick, Kasandra</subfield><subfield code="t">Adenosine Receptors : Pharmacology, Functions and Therapeutic Aspects</subfield><subfield code="d">Hauppauge : Nova Science Publishers, Inc.,c2014</subfield><subfield code="z">9781634634540</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-NLEBK</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-029761544</subfield></datafield></record></collection> |
| id | DE-604.BV044358913 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:50:44Z |
| institution | BVB |
| isbn | 9781634634717 1634634713 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-029761544 |
| oclc_num | 898279089 |
| open_access_boolean | |
| physical | 1 online resource |
| psigel | ZDB-4-NLEBK |
| publishDate | 2014 |
| publishDateSearch | 2014 |
| publishDateSort | 2014 |
| publisher | Nova Biomedical |
| record_format | marc |
| series2 | Pharmacology-research, safety testing, and regulation series |
| spelling | Adenosine receptors pharmacology, functions and therapeutic aspects Kasandra Warrick, editor New York Nova Biomedical [2014] © 2015 1 online resource txt rdacontent c rdamedia cr rdacarrier Pharmacology-research, safety testing, and regulation series ADENOSINE RECEPTORS: PHARMACOLOGY, FUNCTIONS AND THERAPEUTIC ASPECTS; ADENOSINE RECEPTORS: PHARMACOLOGY, FUNCTIONS AND THERAPEUTIC ASPECTS; Library of Congress Cataloging-in-Publication Data; Contents; Preface; Chapter I: Anti-Inflammatory and Immunosuppressive Actions of Adenosine A2A Receptor in Ischemia-Reperfusion Injury after Organ Transplantation; Abstract; Introduction; 1.1. Adenosine and Adenosine Receptors; 1.2. Anti-Inflammatory Mechanisms of A2AR Activation; 1.3. Role of A2AR in Lung IRI; 1.4. Role of A2AR in Kidney IRI; 1.5. Role of A2AR in Cardiac IRI 1.6. Role of A2AR in Liver IRI1.7. Role of A2AR in Pancreas IRI; 1.8. Clinical Experience with A2AR Agonists; Conclusion; References; Chapter II: Adenosine Receptors in the Vasculature: Physiology, Pharmacology and Therapeutic Perspectives; Abstract; 1. Introduction; 2. Adenosine Bioavailability; 2.1. Adenosine Formation and Catabolism; 2.2. Adenosine Transport; 2.2.1. Equilibrative Nucleoside Transporters; 2.2.2. Concentrative Transporters; 2.2.3. Adenosine Transport Inhibition; 3. Adenosine Receptors; 3.1. Interplay between Nucleoside Transport and Adenosine Receptor Activity 3.2. Molecular Structure and Ligand Binding of Adenosine Receptors3.3. Signaling Pathways; 3.4. Adenosine Receptors Distribution; 3.4.1. Vascular Wall: Intima, Media and Adventitia; 3.4.2. Adenosine Receptors in the Vascular Wall; 3.4.2.1. Intima Layer; 3.4.2.2. Media Layer; 3.4.2.3. Adventitial Layer; 4. Therapeutic Potential of Adenosine Receptor Ligands; Conclusion; References; Chapter III: Insights on the Role of Adenosine and Adenosine Receptors on Melanoma: New Therapeutic Strategies; Abstract; Introduction; 1. Adenosine; 1.1. Formation and Metabolism; 1.2. Adenosine Receptors 1.3. Adenosine Receptors in Cancer1.3.1. Adenosine Receptors in Melanoma; 2. Melanoma; 2.1. Signalling Pathways Involved in Melanoma Progression; 2.1.1. Mitogen-Activated Protein Kinase Pathway; 2.1.2. Phosphatidylinositol-3-Kinase Pathway; 2.2. Therapies for Metastatic Melanoma; 3. New Insights; 3.1. Characterization of Adenosine Receptor Expression in Melanoma Cell Lines; 3.2. Inosine Strongly Enhances Human C32 Melanoma Cells Proliferation through PLC-PKC-MEK1/2-ERK1/2 and PI3K Pathways 3.3. Potentiation of Cytotoxicity of Paclitaxel in Combination with Cl-IB-MECA in Human C32 Metastatic Melanoma Cells: A New Possible Therapeutic Strategy for Melanoma3.4. Combination of Cl-IB-MECA with Paclitaxel Is a Highly Effective Cytotoxic Therapy Causing mTOR-Dependent Autophagy and Mitotic Catastrophe on Human Melanoma Cells; 3.5. The Combination of Cl-IB-MECA with Paclitaxel: A New Anti-Metastatic Therapeutic Strategy for Melanoma; Conclusion; References; Chapter IV: Urinary Bladder Disorders: Is Adenosine Friend or Foe?; Abstract; Introduction Adenosine is a ubiquitous adenine base purine that mediates diverse biological and physiological processes in the cardiovascular system, both in cardiac and vascular tissues. Adenosine was reported to be involved in smooth muscle contraction, neurotransmission/neuromodulation, immune response and inflammation, platelet aggregation and modulation of cardiac function. Adenosine availability, in the extracellular space, depends on its release from a variety of cell types, as a result of adenosine triphosphate (ATP) enzymatic breakdown of both intra- and extracellular adenine nucleotides and intra MEDICAL / Pharmacology bisacsh Adenosine / Physiological effect fast Adenosine / Receptors fast Medizin Adenosine Receptors Adenosine Physiological effect Warrick, Kasandra edt Erscheint auch als Druck-Ausgabe Warrick, Kasandra Adenosine Receptors : Pharmacology, Functions and Therapeutic Aspects Hauppauge : Nova Science Publishers, Inc.,c2014 9781634634540 |
| spellingShingle | Adenosine receptors pharmacology, functions and therapeutic aspects ADENOSINE RECEPTORS: PHARMACOLOGY, FUNCTIONS AND THERAPEUTIC ASPECTS; ADENOSINE RECEPTORS: PHARMACOLOGY, FUNCTIONS AND THERAPEUTIC ASPECTS; Library of Congress Cataloging-in-Publication Data; Contents; Preface; Chapter I: Anti-Inflammatory and Immunosuppressive Actions of Adenosine A2A Receptor in Ischemia-Reperfusion Injury after Organ Transplantation; Abstract; Introduction; 1.1. Adenosine and Adenosine Receptors; 1.2. Anti-Inflammatory Mechanisms of A2AR Activation; 1.3. Role of A2AR in Lung IRI; 1.4. Role of A2AR in Kidney IRI; 1.5. Role of A2AR in Cardiac IRI 1.6. Role of A2AR in Liver IRI1.7. Role of A2AR in Pancreas IRI; 1.8. Clinical Experience with A2AR Agonists; Conclusion; References; Chapter II: Adenosine Receptors in the Vasculature: Physiology, Pharmacology and Therapeutic Perspectives; Abstract; 1. Introduction; 2. Adenosine Bioavailability; 2.1. Adenosine Formation and Catabolism; 2.2. Adenosine Transport; 2.2.1. Equilibrative Nucleoside Transporters; 2.2.2. Concentrative Transporters; 2.2.3. Adenosine Transport Inhibition; 3. Adenosine Receptors; 3.1. Interplay between Nucleoside Transport and Adenosine Receptor Activity 3.2. Molecular Structure and Ligand Binding of Adenosine Receptors3.3. Signaling Pathways; 3.4. Adenosine Receptors Distribution; 3.4.1. Vascular Wall: Intima, Media and Adventitia; 3.4.2. Adenosine Receptors in the Vascular Wall; 3.4.2.1. Intima Layer; 3.4.2.2. Media Layer; 3.4.2.3. Adventitial Layer; 4. Therapeutic Potential of Adenosine Receptor Ligands; Conclusion; References; Chapter III: Insights on the Role of Adenosine and Adenosine Receptors on Melanoma: New Therapeutic Strategies; Abstract; Introduction; 1. Adenosine; 1.1. Formation and Metabolism; 1.2. Adenosine Receptors 1.3. Adenosine Receptors in Cancer1.3.1. Adenosine Receptors in Melanoma; 2. Melanoma; 2.1. Signalling Pathways Involved in Melanoma Progression; 2.1.1. Mitogen-Activated Protein Kinase Pathway; 2.1.2. Phosphatidylinositol-3-Kinase Pathway; 2.2. Therapies for Metastatic Melanoma; 3. New Insights; 3.1. Characterization of Adenosine Receptor Expression in Melanoma Cell Lines; 3.2. Inosine Strongly Enhances Human C32 Melanoma Cells Proliferation through PLC-PKC-MEK1/2-ERK1/2 and PI3K Pathways 3.3. Potentiation of Cytotoxicity of Paclitaxel in Combination with Cl-IB-MECA in Human C32 Metastatic Melanoma Cells: A New Possible Therapeutic Strategy for Melanoma3.4. Combination of Cl-IB-MECA with Paclitaxel Is a Highly Effective Cytotoxic Therapy Causing mTOR-Dependent Autophagy and Mitotic Catastrophe on Human Melanoma Cells; 3.5. The Combination of Cl-IB-MECA with Paclitaxel: A New Anti-Metastatic Therapeutic Strategy for Melanoma; Conclusion; References; Chapter IV: Urinary Bladder Disorders: Is Adenosine Friend or Foe?; Abstract; Introduction Adenosine is a ubiquitous adenine base purine that mediates diverse biological and physiological processes in the cardiovascular system, both in cardiac and vascular tissues. Adenosine was reported to be involved in smooth muscle contraction, neurotransmission/neuromodulation, immune response and inflammation, platelet aggregation and modulation of cardiac function. Adenosine availability, in the extracellular space, depends on its release from a variety of cell types, as a result of adenosine triphosphate (ATP) enzymatic breakdown of both intra- and extracellular adenine nucleotides and intra MEDICAL / Pharmacology bisacsh Adenosine / Physiological effect fast Adenosine / Receptors fast Medizin Adenosine Receptors Adenosine Physiological effect |
| title | Adenosine receptors pharmacology, functions and therapeutic aspects |
| title_auth | Adenosine receptors pharmacology, functions and therapeutic aspects |
| title_exact_search | Adenosine receptors pharmacology, functions and therapeutic aspects |
| title_full | Adenosine receptors pharmacology, functions and therapeutic aspects Kasandra Warrick, editor |
| title_fullStr | Adenosine receptors pharmacology, functions and therapeutic aspects Kasandra Warrick, editor |
| title_full_unstemmed | Adenosine receptors pharmacology, functions and therapeutic aspects Kasandra Warrick, editor |
| title_short | Adenosine receptors |
| title_sort | adenosine receptors pharmacology functions and therapeutic aspects |
| title_sub | pharmacology, functions and therapeutic aspects |
| topic | MEDICAL / Pharmacology bisacsh Adenosine / Physiological effect fast Adenosine / Receptors fast Medizin Adenosine Receptors Adenosine Physiological effect |
| topic_facet | MEDICAL / Pharmacology Adenosine / Physiological effect Adenosine / Receptors Medizin Adenosine Receptors Adenosine Physiological effect |
| work_keys_str_mv | AT warrickkasandra adenosinereceptorspharmacologyfunctionsandtherapeuticaspects |